Literature DB >> 28275184

RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction.

Kelly M Marno1, Eithne O'Sullivan1, Christopher E Jones1, Julieta Díaz-Delfín1, Claire Pardieu1, Richard D Sloan1, Áine McKnight2.   

Abstract

Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) replication in human cells is restricted at early postentry steps by host inhibitory factors. We previously described and characterized an early-phase restriction of HIV-1 and -2 replication in human cell lines, primary macrophages, and peripheral blood mononuclear cells. The restriction was termed lentiviral restriction 2 (Lv2). The viral determinants of Lv2 susceptibility mapped to the HIV-2 envelope (Env) and capsid (CA). We subsequently reported a whole-genome small interfering RNA screening for factors involved in HIV that identified RNA-associated early-stage antiviral factor (REAF). Using HIV-2 chimeras of susceptible and nonsusceptible viruses, we show here that REAF is a major component of the previously described Lv2 restriction. Further studies of the viral CA demonstrate that the CA mutation I73V (previously called I207V), a potent determinant for HIV-2, is a weak determinant of susceptibility for HIV-1. More potent CA determinants for HIV-1 REAF restriction were identified at P38A, N74D, G89V, and G94D. These results firmly establish that in HIV-1, CA is a strong determinant of susceptibility to Lv2/REAF. Similar to HIV-2, HIV-1 Env can rescue sensitive CAs from restriction. We conclude that REAF is a major component of the previously described Lv2 restriction.IMPORTANCE Measures taken by the host cell to combat infection drive the evolution of pathogens to counteract or sidestep them. The study of such virus-host conflicts can point to possible weaknesses in the arsenal of viruses and may lead to the rational design of antiviral agents. Here we describe our discovery that the host restriction factor REAF fulfills the same criteria previously used to describe lentiviral restriction (Lv2). We show that, like the HIV-2 CA, the CA of HIV-1 is a strong determinant of Lv2/REAF susceptibility. We illustrate how HIV counteracts Lv2/REAF by using an envelope with alternative routes of entry into cells.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Lv2; REAF; antiviral

Mesh:

Substances:

Year:  2017        PMID: 28275184      PMCID: PMC5411576          DOI: 10.1128/JVI.01228-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1.

Authors:  A Fassati; S P Goff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Cellular entry via an actin and clathrin-dependent route is required for Lv2 restriction of HIV-2.

Authors:  I P Harrison; A McKnight
Journal:  Virology       Date:  2011-04-22       Impact factor: 3.616

3.  Expression cloning of new receptors used by simian and human immunodeficiency viruses.

Authors:  H K Deng; D Unutmaz; V N KewalRamani; D R Littman
Journal:  Nature       Date:  1997-07-17       Impact factor: 49.962

4.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

5.  HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection.

Authors:  Imma Clotet-Codina; Berta Bosch; Jordi Senserrich; María Teresa Fernández-Figueras; Ruth Peña; Ester Ballana; Margarita Bofill; Bonaventura Clotet; José A Esté
Journal:  Antiviral Res       Date:  2009-04-05       Impact factor: 5.970

6.  HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes.

Authors:  Kosuke Miyauchi; Yuri Kim; Olga Latinovic; Vladimir Morozov; Gregory B Melikyan
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

7.  Fates of retroviral core components during unrestricted and TRIM5-restricted infection.

Authors:  Sebla B Kutluay; David Perez-Caballero; Paul D Bieniasz
Journal:  PLoS Pathog       Date:  2013-03-07       Impact factor: 6.823

Review 8.  Interactions between HIV-1 and the cell-autonomous innate immune system.

Authors:  Greg J Towers; Mahdad Noursadeghi
Journal:  Cell Host Microbe       Date:  2014-07-09       Impact factor: 21.023

Review 9.  Virus entry: open sesame.

Authors:  Mark Marsh; Ari Helenius
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

10.  HIV-1 evades innate immune recognition through specific cofactor recruitment.

Authors:  Mahdad Noursadeghi; Greg J Towers; Jane Rasaiyaah; Choon Ping Tan; Adam J Fletcher; Amanda J Price; Caroline Blondeau; Laura Hilditch; David A Jacques; David L Selwood; Leo C James
Journal:  Nature       Date:  2013-11-06       Impact factor: 49.962

View more
  4 in total

1.  HIV-1 Accessory Protein Vpr Interacts with REAF/RPRD2 To Mitigate Its Antiviral Activity.

Authors:  Kelly M Marno; Rebecca Pike; Joseph M Gibbons; Wing-Yiu Jason Lee; Christopher E Jones; Babatunji W Ogunkolade; Claire Pardieu; Alexander Bryan; Rebecca Menhua Fu; Gary Warnes; Paul A Rowley; Richard D Sloan; Áine McKnight
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

Review 2.  Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane.

Authors:  Toshana L Foster; Suzanne Pickering; Stuart J D Neil
Journal:  Front Immunol       Date:  2018-01-04       Impact factor: 7.561

Review 3.  Structure, Function, and Interactions of the HIV-1 Capsid Protein.

Authors:  Eric Rossi; Megan E Meuser; Camille J Cunanan; Simon Cocklin
Journal:  Life (Basel)       Date:  2021-01-29

Review 4.  HIV-1 capsid variability: viral exploitation and evasion of capsid-binding molecules.

Authors:  Akatsuki Saito; Masahiro Yamashita
Journal:  Retrovirology       Date:  2021-10-26       Impact factor: 4.602

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.